A hefty insider share sale has cast a shadow over BioNTech’s recent rally just days before the company is set to unveil its first-quarter results. Chief Operating Officer Sierk Poetting offloaded shares worth roughly $5.5 million through a pre-arranged trading plan, reducing his indirect holdings by more than 11%. He retains nearly 400,000 shares. While market observers typically view such 10b5-1 plan sales as routine, the timing — ahead of a pivotal earnings release on May 5 — has given some investors pause.
The transaction briefly cooled the stock’s upward momentum. By Friday midday, BioNTech’s American depositary receipts traded at €89.95 in Frankfurt, though the shares have still gained a robust 17% over the past month, clawing back ground from recent lows. Across the Atlantic, the stock closed at €92.70 on Thursday, comfortably above its 50-day moving average, before some profit-taking set in.
A Costly Transformation Takes Shape
The Mainz-based biotech is in the throes of an expensive metamorphosis. Once synonymous with the Covid-19 vaccine, the company is now pivoting hard into oncology, building a broad pipeline of cancer therapies. That research offensive comes with a hefty price tag. BioNTech ended 2025 with €17.2 billion in cash and securities — a formidable war chest that management is burning through at an accelerating rate.
The financial strain is already visible. In the final quarter of last year, revenue shrank to just over €907 million, and the company posted an adjusted net loss of roughly €80 million. The collapse in Covid vaccine sales is leaving deep scars on the balance sheet. For the current year, BioNTech forecasts revenue of between €2.0 billion and €2.3 billion, while research and development spending is expected to hit as much as €2.5 billion — meaning the company will spend more on drug development than it brings in from sales.
Should investors sell immediately? Or is it worth buying BioNTech?
Pipeline Progress Fuels Analyst Optimism
Despite the near-term financial headwinds, the clinical pipeline is generating real excitement. Bank of America recently lifted its price target to $130 with a “Buy” rating, citing strong Phase 2 data for the antibody-drug conjugate Trastuzumab Pamirtecan (T-Pam). In advanced endometrial cancer, the drug posted a response rate of nearly 48%, which jumped to 73% among patients with high HER2 expression. BioNTech plans to file for US approval in 2026, while a regulatory review for breast cancer is already underway in China.
Analysts on average see the stock hitting roughly $137, implying significant upside from current levels. The shift in investor focus toward rare diseases and immunology within the mRNA space is also working in BioNTech’s favor. The company aims to launch six additional Phase 3 trials this year, underscoring the breadth of its oncology ambitions.
A Pivotal Month Ahead
All eyes are now on May 5, when management will present first-quarter numbers. Investors are hungry for concrete updates on clinical trial progress and a reliable financial outlook for the remainder of the year. Any delays in the late-stage oncology pipeline would quickly put pressure on the current valuation.
Ten days later, the annual general meeting will take place. Shareholders will vote on expanding the supervisory board with two new oncology specialists and approve a new authorized capital structure. The dual events — earnings and the AGM — will test whether BioNTech can convince the market that its expensive pivot is on track. The €17.2 billion cushion may be deep, but it won’t last forever.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from April 24 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 24.
BioNTech: Buy or sell? Read more here...
